Pfizer will present 57 infectious disease abstracts at IDWeek 2026, including Phase 3 Lyme vaccine findings, new pediatric pneumococcal data and real-world RSV effectiveness studies. The programme highlights pipeline progress while leaving important regulatory and clinical questions unresolved.
Arrowhead Pharmaceuticals has reported up to 73% mean reduction in cerebrospinal-fluid tau at Day 105 after subcutaneous ARO-MAPT treatment in healthy volunteers. The findings support central nervous system target engagement and a potential quarterly dosing schedule, but cognitive benefit and effects on brain tau pathology remain unproven.
Pilatus Biosciences has dosed its first patient in Hong Kong in the ongoing Phase 1 study of PLT012, an investigational CD36-targeting antibody for advanced cancers. The new hepatocellular carcinoma cohort will examine safety, early clinical activity and biomarkers associated with tumor metabolism and immune suppression.
Ironfist Therapeutics reports that its lutetium-177 Tamrada nanomedicine more than doubled survival when combined with anti-PD-1 therapy in a resistant pancreatic cancer mouse model. The company is preparing a copper-64 imaging study for early 2027, but no human efficacy results are available.
Akamis Bio has completed enrollment of 33 patients in its Phase 1b FORTRESS study of NG-350A combined with chemoradiotherapy for mismatch repair-proficient rectal cancer. Earlier results showed a 50% composite response in ten patients, while the full dataset is expected in the first half of 2027.
Coya Therapeutics plans to extend treatment beyond 48 weeks for eligible ALSTARS participants receiving COYA 302 for amyotrophic lateral sclerosis. The decision follows completion of targeted enrollment, while randomized efficacy results remain expected in early 2027 and a separate frontotemporal dementia study has been delayed.
Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?
Vir Biotechnology and Gilead Sciences have agreed to develop three dual-masked T-cell engager programmes under a deal worth up to approximately $1.88 billion. The $90 million upfront package includes cash and equity, while most of the headline value depends on future development and commercial milestones.
The FDA has accepted Pierre Fabre's resubmitted application for tabelecleucel, setting a March 31, 2027 decision date. The review follows two rejection letters, including a January 2026 dispute over whether the ALLELE study adequately establishes effectiveness.
Sarepta has reported up to 80% knockdown of DMPK RNA in both the nucleus and cytoplasm of patient-derived muscle cells, alongside correction of abnormal RNA splicing in preclinical models. The findings address a central delivery challenge in myotonic dystrophy type 1, while an ongoing Phase 1/2 trial will determine whether the mechanism translates into patient